Novartis Baltics

Home
Latvia
Riga
Novartis Baltics

Our purpose is to reimagine medicine to improve and extend people's lives. See our community guidelines: https://go.novartis.social/47E2z0k

We use innovative science and technology to address some of society's most challenging healthcare issues. Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

02/10/2025

🌟 We’re thrilled to announce a major milestone for Novartis Baltics and Rīgas Stradiņa universitāte (Riga Stradins University) | RSU Inovāciju centrs! 🤝

Agrita Kiopa, Vice-Rector for Science, RSU, Ramune Lauciuviene, Country President Baltics and Ukraine, and Sweta Ghelani, European Central Cluster Head, signed a Memorandum of Understanding to launch a Medical Traineeship Program - an exciting step forward in our long-term partnership and investment in future healthcare talent.

This collaboration is all about connecting, sharing perspectives, and confirming our shared commitment to meaningful cooperation. Together, we’re nurturing the next generation of healthcare leaders by providing hands-on experience across key functions at Novartis, fostering innovation, and building capacity in clinical research, regulatory science, and access strategy.

By joining forces, we encourage collaboration between academia and industry, and contribute to the growth of the healthcare ecosystem in Latvia and the Baltics. 🌍💡

🙏 A heartfelt thank you to our incredible local and cluster teams for making this possible Irena Teterina, Dita Erna Sile, Guna Logina, Nuria Jornet.

We look forward to supporting future healthcare professionals on their journey! 🚀

01/10/2025

🫀 On World Heart Day, we came together in Tallinn to advance cardiovascular care — because every heartbeat deserves our best effort

📅 On September 30th, Ravimitootjate liit (the Association of Pharmaceutical Manufacturers of Estonia (APME)) organized a roundtable that brought together experts from Sotsiaalministeerium (the Ministry of Social Affairs), Tervisekassa (the Estonian Health Insurance Fund), healthcare professionals, and patient representatives. The focus: improving the treatment journey for patients with myocardial infarction and heart failure.

💡 Inspired by the Estonian Health Insurance Fund’s care pathway initiative, the discussion highlighted key challenges and opportunities:

⚠️ Fragmented patient journeys - many don’t receive or stay on necessary treatment
🔄 Communication gaps between hospitals, GPs, and rehabilitation services
🧑‍⚕️ The critical role of nurse coordinators and support staff - but there’s a shortage
❓ Lack of clear responsibilities across the system
🔗 Need for integrated care, better data sharing, and understandable patient information
💻 Future solutions like digital care plans, health data warehouses, and stronger prevention strategies

🗣️ Karin Varrak, Novartis Country Business Head Estonia and Head of APME’s Cardiovascular Working Group, shared: “What stood out to me was the shared commitment to improving patient outcomes. Small steps matter, but lasting impact requires systemic change and cross-sector collaboration. Healthcare must be treated as an investment in our future.”

🙏 Thank you to all participants for your commitment. On , we’re reminded: collaboration is key — and no heart should be lost too soon. ❤️

25/09/2025

🌟 Baltic Magic in Motion🌟

This week, the Novartis European Central Cluster (ECC) leadership team brought an incredible wave of energy and inspiration to Riga for our business review. From the very first moment, the spirit of collaboration, bold ambition, and relentless drive for excellence was palpable. Together, we went beyond the numbers - we celebrated our journey as the No. 1 company in the Baltics, leading in every therapy area we play in, and shaping the future of healthcare with courage and innovation. 🚀

Throughout the visit, we engaged in in-depth discussions on performance, strategy, and the unique strengths that make the Baltics a true benchmark region for Novartis. Our teams in Lithuania, Latvia, and Estonia continue to set new standards - delivering continued growth, pioneering digital health solutions, and building partnerships that make a real difference for patients and communities. 💡🌍

Ramune Lauciuviene, Country President Baltics & Ukraine, shared:
“There is truly a Baltic Magic in Motion. As the No. 1 company in the Baltics and a leader in every therapy area we play in, I am incredibly proud of our high-performing teams across all three countries. Their ambition, resilience, and passion for patients set the standard for excellence. Together, we are not just achieving results - we are raising the bar and inspiring each other to always do better.”

Sweta Ghelani, ECC Head, perspective on the Baltic team:
“The Baltics team is simply - they find a way to overcome barriers here. What impresses me most is the unique Baltic mindset: they are ambitious, accountable and collaborative. They set the benchmark high and I believe that their innovative and pragmatic approach to solving problems could be exported to other countries as a shining example of what’s possible when ambition meets teamwork. When they commit as one team, they deliver for patients.”

🔥 Let’s keep the momentum going! This visit is not just a milestone - it’s a call to action for all of us to dream bigger, act bolder, and continue aiming for excellence in the Baltics and beyond. Together, we are making magic happen - one breakthrough, one patient, one team at a time. 💪🌍

24/09/2025

🩺 Latvia’s people have spoken: healthcare is the nation’s top priority for next year’s budget!

35% of Latvians believe health should be at the center of government focus - far ahead of economic development or security - according to the new “Health Economics Barometer 2025” survey, presented by Inovācijas Veselībā (Association of International Research-based Pharmaceuticals Manufacturers in Latvia) and partners.

Yet the data also highlight urgent challenges:

• 77.2% cite long waiting for doctors and specialists
• 61.5% say state-funded services are insufficient
• 36.8% are concerned about medicine accessibility and price
• 41% skipped care due to financial reasons
• State healthcare spending is just 4.6% of GDP, (target: 6% by 2027)

At Novartis, we believe that strategic investment in healthcare is not just a moral imperative, but a driver of national resilience and economic growth. The Draghi report on EU competitiveness explicitly highlights the pharmaceutical sector as one of the top three strategic sectors for the EU’s future, calling for increased investment and innovation.

Yet Latvia continues to lag behind in key health indicators:

• 642 days to medicine availability (EU avg: 578 days)
• Only 31 innovative medicines availability (EU avg; 80)
• Healthy life years: 52.7 years (EU avg: 63.1)
• Preventable and treatable mortality per 100k: 543 (EU avg: 258)

“The government needs to be bold and take a decision to invest in healthcare. The evidence is clear: investing in health delivers high returns for the national economy and strengthens society’s resilience—including for defense. Latvia must acknowledge this and act now.” - Liene Silina, Country Business Head Latvia, Chairwoman of SIFFA.

Let’s work together - industry, government, and society - to ensure every person in Latvia has access to the care they need.

🏥

19/09/2025

Novartis Baltics joined Life Sciences Baltics, the leading life sciences conference in the region. 🔬

Our session, “From Promise to Progress: Radiopharmaceuticals Shaping the Future of Oncology”, gathered experts from clinics, academia and policymakers to discuss Lithuanian healthcare readiness for emerging radioligand therapies (RLTs). 🧬

Session participants highlighted that RLTs are a breakthrough shift in precision oncology, as highly effective cancer treatments, making their availability a priority. These therapies' innovation in this field calls for coordinated efforts and strong institutional partnerships. Their successful adoption requires systemic progress in regulation, infrastructure, and workforce capacity. National health leaders emphasize readiness for regulation, trust in scientific expertise, and a strategic focus on investing in transformative medical innovation - innovation that enables people to return to their families, communities, and economies with longer, healthier lives.

Ben Gommers, Novartis Executive Director Public Affairs, Western European Cluster said: “Only by working together across sectors can we make a difference. We must ensure that patients have affordable and easy access to treatment.”

We are thankful to all speakers for advancing this important dialogue on the future of oncology care.

FA-11515874 2025/09

19/09/2025

🌟 Celebrating a forward-looking initiative to accelerate health innovation in Lithuania!

Earlier this week, Ramunė Lauciuvienė, Country President Baltics and Ukraine, represented Novartis Baltics in a meaningful collaboration with leading institutions - Inovacijų agentūra, Valstybės duomenų agentūra, EIT Health, EIT Health InnoStars represented by Lietuvos sveikatos mokslų universitetas / LSMU and KTU Kauno technologijos universitetas/Kaunas University of Technology - to sign the Memorandum of Understanding for the Data Pilot 2.0 initiative. We are honored to have been invited to contribute and humbled by the opportunity to support data-driven innovation in healthcare.

This strategic initiative aims to build a dynamic, multidisciplinary health data ecosystem. By leveraging advanced analytics, real-world evidence, and cutting-edge methodologies, we’re empowering startups and experts to tackle critical challenges in oncology, rare diseases, personalized medicine, and beyond.

Together, we’re accelerating the path from visionary ideas to tangible impact - improving lives, strengthening healthcare systems, and shaping a future where data-driven care is not just possible, but powerful.

Let’s keep pushing boundaries, sharing knowledge, and building a truly competitive health innovation landscape.

18/09/2025

🧡 Celebrating World Patient Safety Day 2025 Across the Baltics! 🧡

At Novartis, patient safety is at the heart of everything we do. This year, we proudly joined the global movement led by the World Health Organization to mark World Patient Safety Day, with a special focus on ensuring safe care for every newborn and every child.

Under the inspiring slogan “Patient safety from the start!” 🌟, our teams in Latvia, Lithuania, and Estonia came together to raise awareness and celebrate the importance of building trust and safety from the very beginning of life.

Our offices were lit up in orange, symbolizing hope, safety, and our shared commitment to better healthcare.

Karolina Valentinavičienė, Country Patient Safety Head Baltics, shared some highlights: "It was a pleasure welcoming our colleagues’ children to the office for a day filled with fun, learning, and discovery, where they also had the opportunity to hear about the vital role of drug safety and how it protects patients – just like them. This wasn’t just a celebration – it was an investment in the next generation.💡👧👦 Together, we’re shaping a future where patient safety is a value we all share. Thank you to everyone who made this day so meaningful.💙"

15/09/2025

🚀 Join us at Life Sciences Baltics 2025 for a forward-looking Novartis session:
"From Promise to Progress: Radiopharmaceuticals Shaping the Future of Oncology"

Discover how radiopharmaceuticals are transforming cancer care and driving innovation in nuclear medicine.

📅 September 17, 2025
🕥 10:10–11:00 AM
📍 Attend in person at Litexpo, Vilnius, Insights Stage

Let’s shape the future of oncology - together.

Agenda - Life Sciences Baltics 2025 - https://lifesciencesbaltics.com/program/

| FA-11510949 2025-09

04/09/2025

🌍 Healthcare Innovation Is a Catalyst of European Innovation

At the recent Bled Strategic Forum, Georg Schroeckenfuchs, Head of Novartis SERCE (Southern, Eastern, Russia & Central Europe) region, joined a high-level panel to discuss how healthcare innovation can be a catalyst for European Competitiveness. The urgency to act is clear: patients across Europe are waiting far too long for access to breakthrough therapies.

⏳ On average, patients wait 578 days for new innovative medicines in Europe. In the Baltics, the delay is even longer – 642 days in Latvia, 713 days in Estonia, and 819 days in Lithuania. This trend is worsening, with patients waiting increasingly longer each year to access new treatment options.

📣 As Georg Schroeckenfuchs emphasized: “Keeping patients at the center is not optional. It is the test of whether Europe remains competitive and whether innovation truly reaches the people who need it most.”

For Europe to stay competitive in life sciences, we must act now:
⏩ Prioritize policies that reward healthcare innovation to drive long-term growth
⏩ Streamline regulatory systems to speed up access
⏩ Ensure equitable availability of therapies across all countries

01/09/2025

What if nuclear medicine could redefine how we treat cancer? That question sparked powerful dialogue during a forward-looking discussion hosted by the National Cancer Centre at the democracy festival Diskusijų festivalis „Būtent!“ in Vilnius, Lithuania.

💡 Key takeaways:

• Lithuania is advancing alongside leading European countries in adopting breakthrough cancer treatment technologies like radioligands.

• Theranostic approach - combining diagnostics and therapy - is ready to be implemented, offering targeted treatment that detects and destroys cancer cells while sparing healthy tissue.

• Healthcare professionals are enthusiastic about the potential to improve patient outcomes through this innovative platform.

• While Lithuania is prepared to launch this technology today, further investment in infrastructure is essential to fully meet patient needs.

Deimantė Stankevičienė, Medical Engagement Partner: “It’s inspiring to see such momentum and commitment to transforming cancer care. Grateful to be part of these conversations that shape the future of medicine.”

| 2025-09 FA-11500223

18/08/2025

🌟 Imagine if I had a secret superpower. What would it be? 🌟

At , we believe that health is the real superpower. Because when people are healthy, they’re empowered to live fully, dream boldly, and shape the future - for themselves and their communities.

So, we asked a few of our colleagues what they would embrace:

🗣️"Imagine if I could give sight to blind people - so they could see the beauty of our country... and our planet. 😊" - Audrone Jurkeviciute, Head of Regulatory Affairs, Baltics

🗣️"Imagine if I could make understanding health data as effortless as breathing, inspiring better choices every day." - Brigitha Kask, Healthcare Solution Lead, Estonia

🗣️"Imagine if I could turn every spoken insult into kind words and every abuse into a helping hand, we'd have a mentally strong and thriving society." - Karina Grudula, Customer Engagement and Solution Partner, Latvia

💬 Now it’s your turn: What would your superpower related to health be?

20/06/2025

The Novartis Latvia team came together to mark the start of Midsummer with our Summer Adventure — a day of connection, collaboration, and nature 🌞

Set against the serene backdrop of Līgatnes river, we began with a fresh open-air breakfast 🥐☕, followed by a scenic hike 🥾 and a hands-on cooking experience🍳🌲

This day was more than just a celebration — it was a reflection of our culture of curiosity, teamwork, and wellbeing 💡🤝💚

May your Midsummer be filled with light and laughter, and the timeless magic of tradition and nature! 🌿🌼🔥

Address

Skanstes Iela 25
Riga
LV-1013

Website

https://www.novartis.com/lv-lv

Alerts

Be the first to know and let us send you an email when Novartis Baltics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Riga?

Novartis Baltics

02/10/2025

01/10/2025

25/09/2025

24/09/2025

19/09/2025

19/09/2025

18/09/2025

15/09/2025

04/09/2025

01/09/2025

18/08/2025

20/06/2025

Address

Website

Alerts

Shortcuts

Share

Category